Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

被引：0
|
作者：
Pietro Lampertico
Stefan Mauss
Marcello Persico
Stephen T. Barclay
Steven Marx
Kristina Lohmann
Mark Bondin
ZhenZhen Zhang
Fiona Marra
Pamela S. Belperio
Heiner Wedemeyer
Steven Flamm
机构：
[1] Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico,Division of Gastroenterology and Hepatolgy, CRC “A.M. and A.Migliavacca” Center for Liver Disease
[2] University of Milan,Department of Pathophysiology and Transplantation
[3] Center for HIV and Hepatogastroenterology,Internal Medicine and Hepatology Unit
[4] University of Salerno,Department of Life Sciences
[5] Glasgow Caledonian University,Department of Veterans Affairs
[6] Gastroenterology,Department of Gastroenterology and Hepatology
[7] Glasgow Royal Infirmary,Department of Gastroenterology, Hepatology and Endocrinology
[8] AbbVie Inc.,undefined
[9] AbbVie Deutschland GmBH Co. KG,undefined
[10] University of Liverpool Hepatology Drug Interactions Group,undefined
[11] VA Palo Alto Healthcare System,undefined
[12] Essen University Hospital,undefined
[13] Leberstiftungs-GmbH Deutschland,undefined
[14] Hannover Medical School,undefined
[15] Northwestern University Feinberg School of Medicine,undefined
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Fibrosis; Hepatitis C; Infectious disease; Review; Therapeutics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4033 / 4042
页数：9
相关论文
共 50 条
  • [31] Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study
    Su, Pei-Yuan
    Chen, Yang-Yuan
    Lai, Jun-Hung
    Chen, Hung-Ming
    Yao, Chih-Ta
    Liu, I-Ling
    Zeng, Ya-Huei
    Huang, Siou-Ping
    Hsu, Yu-Chun
    Wu, Shun-Sheng
    Siao, Fu-Yuan
    Yen, Hsu-Heng
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (22)
  • [32] Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C-Results of a Multicenter EpiTer-2 Study
    Pawlowska, Malgorzata
    Dobrowolska, Krystyna
    Moppert, Justyna
    Pokorska-Spiewak, Maria
    Purzynska, Mariola
    Marczynska, Magdalena
    Zarebska-Michaluk, Dorota
    Flisiak, Robert
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (21)
  • [33] Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
    Atsushi Naganuma
    Kazuaki Chayama
    Kazuo Notsumata
    Edward Gane
    Graham R. Foster
    David Wyles
    Paul Kwo
    Eric Crown
    Abhi Bhagat
    Federico J. Mensa
    Tetsuya Otani
    Lois Larsen
    Margaret Burroughs
    Hiromitsu Kumada
    Journal of Gastroenterology, 2019, 54 : 752 - 761
  • [34] EFFICACY AND SAFETY OF 8-WEEK GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF PATIENTS WITH ACUTE HEPATITIS C: A SINGLE-ARM RETROSPECTIVE STUDY
    Pol, Stanislas
    Thompson, Alexander J.
    Collins, Michelle
    Venier, Elisa
    Cotte, Laurent
    Laguno, Monserrat
    Mera, Jorge Raul
    Reiberger, Thomas
    Burroughs, Margaret
    Semizarov, Dimitri G.
    Iacob, Alexandru M.
    Welhaven, Anne
    Fredrick, Linda
    Doyle, Joseph S.
    HEPATOLOGY, 2024, 79 (02) : E81 - E82
  • [35] Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle Glaucoma
    Constance O. Okeke
    Eitan S. Burstein
    Valerie Trubnik
    James E. Deom
    Michael S. Cooper
    Desirae A. Brinkley
    J. James Thimons
    Alexander J. Kabiri
    Kerry M. Gelb
    Ophthalmology and Therapy, 2020, 9 : 1041 - 1053
  • [36] Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts
    Feld, Jordan J.
    Forns, Xavier
    Dylla, Douglas E.
    Kumada, Hiromitsu
    de Ledinghen, Victor
    Wei, Lai
    Brown, Robert S., Jr.
    Flisiak, Robert
    Lampertico, Pietro
    Thabut, Dominique
    Bondin, Mark
    Tatsch, Fernando
    Burroughs, Margaret
    Marcinak, John
    Zhang, Zhenzhen
    Emmett, Amanda
    Jacobson, Ira M.
    JOURNAL OF VIRAL HEPATITIS, 2022, 29 (12) : 1050 - 1061
  • [37] REAL-WORLD EXPERIENCE OF 12-WEEK DAA REGIMEN OF GLECAPREVIR AND PIBRENTASVIR IN JAPANESE PATIENTS WITH CHRONIC HCV INFECTION
    Yasuda, Satoshi
    Toyoda, Hidenori
    Iio, Etsuko
    Akahane, Takehiro
    Fujioka, Shinichi
    Kunihiko, Tsuji
    Shimada, Noritomo
    Ishikawa, Toru
    Tachi, Yoshihiko
    Hotta, Naoki
    Tanaka, Yasuhito
    Kumada, Takashi
    HEPATOLOGY, 2019, 70 : 928A - 928A
  • [38] Real-world study on the efficacy and safety of different treatment regimens in treatment-naïve CHB patients with high viral load
    Wu, Xue
    Yan, Qin
    Jiang, Chunmei
    Fan, Rongshan
    Li, Sheling
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [39] PERICOACH® 8-WEEK STRUCTURED PROGRAMMING REAL-WORLD DATA AND IMPACT OF CLINICAL ENGAGEMENT
    Cornelius, C.
    Monsour, M.
    Noursalehi, M.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2019, 30 : S157 - S158
  • [40] Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts
    Forns, Xavier
    Feld, Jordan J.
    Dylla, Douglas E.
    Pol, Stanislas
    Chayama, Kazuaki
    Hou, Jinlin
    Heo, Jeong
    Lampertico, Pietro
    Brown, Ashley
    Bondin, Mark
    Tatsch, Fernando
    Burroughs, Margaret
    Marcinak, John
    Zhang, Zhenzhen
    Emmett, Amanda
    Gordon, Stuart C.
    Jacobson, Ira M.
    ADVANCES IN THERAPY, 2021, 38 (06) : 3409 - 3426
12345